

Medtronic

ESH Guidelines recommend renal denervation

The turning point in hypertension care

for uncontrolled hypertension patients¹

The European Society of Hypertension (ESH), endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH), now recommends renal denervation (RDN) as a **safe and effective complementary hypertension treatment strategy**.¹

Patient selection criteria



Patients with an eGFR >40 ml/min/1.73m² who have **uncontrolled BP** despite the use of antihypertensive drug combination therapy* or if drug treatment elicits serious side effects and poor quality of life. (Class II)



Patients with **resistant hypertension** if eGFR is >40 ml/min/1.73m². (Class II)

Additional recommendations



Selection of patients should be done in a **shared decision-making process** after objective and complete patient's information. (Class I)



Performed in experienced specialised centers to guarantee **appropriate selection of eligible patients** and completeness of the denervation procedure. (Class I)

* "Patients may be on fewer than three drugs at the time of their selection for RDN"

[Read the guidelines](#)

Significant, safe and sustained BP reductions²⁻⁷

The Simplicity™ Blood Pressure procedure is supported by published **clinical evidence unmatched** in scope, quantity, and quality, with **> 25,000 patients** treated globally^{8†} and **>4,000 patients** enrolled in the global clinical program^{9†}.

Explore the evidence

**>9
mmHg**
reduction in OSBP at
primary endpoint²⁻⁵

A hand is shown holding a thin catheter. The catheter has a small sensor at the tip, which is emitting a blue and white waveform. This waveform is superimposed on a large, solid pink circle. The text '>9 mmHg reduction in OSBP at primary endpoint²⁻⁵' is written in white on the pink circle. The background of the entire page is white with a pattern of grey circles of varying sizes, some of which are semi-transparent.

References:

1. Mancia G, et al. Journal of Hypertension 2023, 41:000-000
 2. Townsend RR, et al. The Lancet. 2017;390(10108):2160-2170.
 3. Böhm M, et al. The Lancet. 2020;395(10234):1444-1451.
 4. Kandzari DE, et al. The Lancet. 2018;391(10137):2346-2355.
 5. Kandzari DE et al, AHA 2022
 6. Schlaich M et al, Kidney Week 2021
 7. Mahfoud F, et al. Lancet 2022; 399: 1401-10.
 8. Medtronic Data on File, RDN Catheter Historic Data, May 2023.
 9. Medtronic Data on File, Patients in clinical program, Mar 2023
- † Includes Simplicity Spyral™ and Flex™ catheters

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

Medtronic

Medtronic.eu/RDN

UC202401077EE © 2023 Medtronic. Medtronic, Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Simplicity Spyral™ multi-electrode renal denervation catheter and Simplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan, or France.